- In June 2024, GlaxoSmithKline plc partnered with a leading digital health company to integrate smart sensor technology into their Ellipta® inhaler. This collaboration aims to provide patients with real-time feedback on their inhalation technique and medication adherence via a connected mobile application, potentially improving treatment outcomes for asthma and COPD.
- In September 2024, GSK announced the launch of a new digital support program designed to complement their inhaled corticosteroids. This program offers personalized reminders, educational resources, and guidance on proper inhaler use, accessible through a dedicated mobile app, aiming to enhance patient self-management and adherence.
